Shares of AbbVie Inc. (NYSE:ABBV) traded at a new 52-week high today of $101.35. So far today approximately 4.7 million shares have been exchanged, as compared to an average 30-day volume of 9.2 million shares.
AbbVie is a drug company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents over half of the company’s current profits.
AbbVie Inc. (NYSE:ABBV) has potential upside of 8.7% based on a current price of $101.29 and analysts’ consensus price target of $110.14.
AbbVie Inc. share prices have moved between a 52-week high of $101.35 and a 52-week low of $62.55 and are now trading 62% above that low price at $101.29 per share.
Receive IBN`s Technical Indicator Alerts
To stay connected with our complimentary IBN alerts, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. IBN has a proven track record and has served 500+ client partners. IBN is the key to more effective market communication.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer